Key Takeaways for Thermo Fisher Scientific Stock as of June 2026
- Analysts rate Thermo Fisher Scientific stock 18 buys, 5 outperforms, 6 holds, and 0 sells, with a mean target of $596, implying around 16% upside from the current price of $513.
- TIKR’s mid-case model values Thermo Fisher Scientific at around $788 by December 2030, implying around 54% total return, or roughly 10% annualized.
- Thermo Fisher raised full-year adjusted EPS guidance to $24.64 to $25.12 after Q1 operational outperformance added $0.13 above prior guidance, and the $9 billion Clario acquisition contributed an additional $0.32 for the full year.
Thermo Fisher Scientific Stock Raises Guidance After Beating EPS by 4% While Absorbing Tariff Headwinds
Thermo Fisher Scientific (TMO) opened 2026 with Q1 revenue of $11.01 billion, up 6% year over year, beating the Street’s $10.86 billion estimate by 1.33%, even as one fewer selling day and 80 basis points of tariff and foreign exchange pressure worked against the quarter. The beat extended to the bottom line, where the result matters most for assessing the stock’s current discount.
Normalized EPS landed at $5.44 against the Street’s $5.24 estimate, a 3.79% outperformance. CFO Jim Meyer explained the composition on the Q1 earnings call: “This included the $0.01 from Clario and $0.13 from strong operational performance, demonstrating our continued active management of the company and the power of the PPI Business System.” That $0.13 operational beat drove the full-year guidance raise directly.
That outperformance came from a divergence across end markets. Pharma and biotech delivered mid-single-digit growth, led by bioproduction and clinical research, which offset low-single-digit declines in academic and government and a mid-single-digit decline in Specialty Diagnostics. The reported 1% organic growth rate understates the underlying pace: adjusted for the lost selling day and pharma services timing, the normalized rate was closer to 3%.
The quarter also closed the $9 billion Clario acquisition on March 24. Clario, a leader in digital endpoint data solutions for clinical trials, contributed $30 million in Q1 revenue and $0.01 of adjusted EPS on a partial-quarter basis, with management guiding approximately $900 million in full-year revenue and $0.32 of full-year EPS contribution.
On Q1 execution and Clario, Thermo Fisher raised full-year revenue guidance to $47.3 billion to $48.1 billion and lifted adjusted EPS guidance to $24.64 to $25.12, representing 8% to 10% growth over 2025.
Wall Street Holds 18 Buys on Thermo Fisher Scientific Stock With a $596 Mean Target
As of June 26, 2026, 27 analysts cover Thermo Fisher Scientific stock with 18 buys, 5 outperforms, and 6 holds against zero sell-side bearish ratings. The mean price target stands at $596, implying around 16% upside from the current price of $513.
The target range runs from $490 on the low end to $750 on the high, reflecting a wide spread in how analysts are weighting the macro drag against Clario accretion and the bioproduction recovery.
Wall Street Expects Thermo Fisher Scientific Stock’s Normalized EPS to Accelerate Through 20% Growth by Q4 2026
Thermo Fisher’s Q1 2026 normalized EPS of $5.44 came in 5.6% above the same quarter last year, outperforming Street estimates by 3.8%. That result established the floor for what management and consensus expect to be a materially stronger second half.
For Q2 2026, analysts estimate normalized EPS of $5.71, representing roughly 7% growth year over year. The step-up from Q1 reflects the disappearance of the selling-day headwind and significantly easier Analytical Instruments comparables, where Q2 2025 was disrupted by the initial tariff implementation.
The ramp accelerates from there. Consensus estimates normalized EPS of $6.37 in Q3 2026 (roughly 10% growth year over year) and $7.34 in Q4 2026 (roughly 12% growth year over year), producing a full-year normalized EPS trajectory that tracks squarely within management’s raised guidance range of $24.64 to $25.12.
Thermo Fisher Scientific Stock’s Normalized EPS Lead Over DHR and IQV Widens Into 2026
Thermo Fisher Scientific’s Q1 2026 normalized EPS of $5.44 ran nearly three times Danaher’s (DHR) $1.94 and nearly twice IQVIA’s (IQV) $2.82 in the same quarter.
The gap holds into the estimates.
Consensus puts TMO at around $7.34 in Q4 2026, against around $2.54 for Danaher and around $3.63 for IQVIA. Danaher is growing faster on a percentage basis at roughly 16% year over year versus TMO’s roughly 12%, but from a base less than a third the size. Thermo Fisher’s Clario acquisition further adds $0.32 in full-year EPS accretion that neither peer carries, widening the absolute lead further into the back half of 2026.
TIKR’s $788 Target on TMO Stock Holds if the EPS Ramp Arrives as Guided
TIKR’s mid-case model values Thermo Fisher Scientific at around $788 by December 2030, implying around 54% total return from the current price of $513, or roughly 10% annualized over approximately 4.5 years.
A 10% annualized return from a large-cap life sciences tools company with an investment-grade balance sheet sits at the high end of what the sector typically offers, which reflects how much ground TMO stock has to recover from its current level relative to intrinsic value.
The Street’s $596 mean target and TIKR’s $788 model sit on the same side of the trade, separated only by time horizon and assumptions about operating leverage.
The path to $788 runs directly through what the Q1 data already showed: operational discipline absorbing macro headwinds while EPS grows, clinical research continuing to take share, bioproduction sustaining its momentum, and Clario contributing an accretive $0.32 annually as integration matures. Thermo Fisher Scientific stock is undervalued at $513 if that execution continues.
Should You Invest in Thermo Fisher Scientific Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher Scientific stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher Scientific alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze TMO stock on TIKR for Free →
